Current and historical daily PE Ratio for VERA (
Vera Therapeutics Inc
) from 2021 to Apr 18 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Vera Therapeutics stock (VERA) PE ratio as of Apr 18 2024 is 0.
More Details
Vera Therapeutics Inc (VERA) PE Ratio (TTM) Chart
Vera Therapeutics Inc (VERA) PE Ratio (TTM) Historical Data
View and export this data going back to 2021. Start your Free Trial
Total 741
- 1
- 2
- 3
- 4
- 5
- 6
- 9
| Vera Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-18 | At Loss | 2024-02-15 | At Loss |
| 2024-04-17 | At Loss | 2024-02-14 | At Loss |
| 2024-04-16 | At Loss | 2024-02-13 | At Loss |
| 2024-04-15 | At Loss | 2024-02-12 | At Loss |
| 2024-04-12 | At Loss | 2024-02-09 | At Loss |
| 2024-04-11 | At Loss | 2024-02-08 | At Loss |
| 2024-04-10 | At Loss | 2024-02-07 | At Loss |
| 2024-04-09 | At Loss | 2024-02-06 | At Loss |
| 2024-04-08 | At Loss | 2024-02-05 | At Loss |
| 2024-04-05 | At Loss | 2024-02-02 | At Loss |
| 2024-04-04 | At Loss | 2024-02-01 | At Loss |
| 2024-04-03 | At Loss | 2024-01-31 | At Loss |
| 2024-04-02 | At Loss | 2024-01-30 | At Loss |
| 2024-04-01 | At Loss | 2024-01-29 | At Loss |
| 2024-03-29 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
| 2024-03-11 | At Loss | 2024-01-08 | At Loss |
| 2024-03-08 | At Loss | 2024-01-05 | At Loss |
| 2024-03-07 | At Loss | 2024-01-04 | At Loss |
| 2024-03-06 | At Loss | 2024-01-03 | At Loss |
| 2024-03-05 | At Loss | 2024-01-02 | At Loss |
| 2024-03-04 | At Loss | 2024-01-01 | At Loss |
| 2024-03-01 | At Loss | 2023-12-29 | At Loss |
| 2024-02-29 | At Loss | 2023-12-28 | At Loss |
| 2024-02-28 | At Loss | 2023-12-27 | At Loss |
| 2024-02-27 | At Loss | 2023-12-26 | At Loss |
| 2024-02-26 | At Loss | 2023-12-22 | At Loss |
| 2024-02-23 | At Loss | 2023-12-21 | At Loss |
| 2024-02-22 | At Loss | 2023-12-20 | At Loss |
| 2024-02-21 | At Loss | 2023-12-19 | At Loss |
| 2024-02-20 | At Loss | 2023-12-18 | At Loss |
| 2024-02-19 | At Loss | 2023-12-15 | At Loss |
| 2024-02-16 | At Loss | 2023-12-14 | At Loss |
Vera Therapeutics Inc (VERA) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Vera Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US92337R1014
Share Class Description:
VERA: Class ADescription
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers